title: [Expression of carbonic anhydrase IX in the breast carcinomas].
abstract: OBJECTIVE
  Carbonic anhydrase IX (CA IX) is one indicator of hypoxia in the tumor and its expression is associated with more aggressive forms of breast cancer. The aim of this study is to point out its own set of correlation between CA IX expression and selected morphological and biological indicators.
  
  
  METHODS
  Cohort prospective study.
  
  
  METHODS
  Department of Pathology of Slovak Medical University and St. Elisabeth Cancer Institute, Bratislava, Slovak Republic.
  
  
  METHODS
  These were 145 cases of breast cancer aged 25 to 85 years (median 59 years) from the Register of the Institute of Pathology and Slovak Medical University and St. Elisabeth Cancer Institute in Bratislava for the period 1. 9. 2012 to 28. 2. 2013. In all cases were examined CA IX, estrogen receptor (ER), progesterone receptor (PR), HER2, p53 and Ki67 by immunohistochemistry. Typing, grading and staging of the disease were evaluated according to the classification systems currently in place.
  
  
  RESULTS
  CA IX expression was demonstrated in 51 cases (35.2%). CA IX positivity correlated with the degree of differentiation (p = 0.0001), with ER status (p <0.0001) and PR (p <0.01) and HER2 (p <0.01) and proliferative activity as measured by Ki67 (p <0.001). HER2-positive cancers and triple-negative cancers were more frequently associated with the expression of CA IX compared with luminal subtypes (p <0.0001). The state of CA IX and age range of the tumor - pT and lymph node status - pN and p53 have not been shown statistically significant correlations.
  
  
  CONCLUSIONS
  CA IX examination in breast cancer provides valuable information on the state of hypoxia in the tumor, thereby supplementing view of prognosis of the disease.
authors.affiliation: Ústav patológie Slovenskej zdravotníckej univerzity a Onkologického ústavu svätej Alžbety, Bratislava, Slovenská republika. kkajo@ousa.sk
authors.forename: K
authors.initials: K
authors.lastname: Kajo
authors.forename: I
authors.initials: I
authors.lastname: Turčan
authors.forename: M
authors.initials: M
authors.lastname: Vallová
authors.forename: T
authors.initials: T
authors.lastname: Laboš
authors.forename: M
authors.initials: M
authors.lastname: Kajo
authors.forename: K
authors.initials: K
authors.lastname: Macháleková
authors.forename: Galbavý
authors.initials: G
authors.lastname: S
authors.forename: P
authors.initials: P
authors.lastname: Zúbor
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000951:Antigens, Neoplasm / Q000737:chemistry / Q000378:metabolism*; D014408:Biomarkers, Tumor / Q000737:chemistry / Q000378:metabolism*; D001943:Breast Neoplasms / Q000453:epidemiology / Q000378:metabolism* / Q000473:pathology; D000071231:Carbonic Anhydrase IX; D002256:Carbonic Anhydrases / Q000737:chemistry / Q000378:metabolism*; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008875:Middle Aged; D011379:Prognosis; D011446:Prospective Studies; D018154:Slovakia / Q000453:epidemiology
chemical_list: D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; C089226:CA9 protein, human; D000071231:Carbonic Anhydrase IX; D002256:Carbonic Anhydrases